AI Article Synopsis

  • Primary hypertrophic osteoarthropathy (PHOA) is a rare disease characterized by symptoms like digital clubbing, bone formation, joint deformities, and skin hypertrophy; however, many patients exhibit incomplete symptom profiles.
  • Diagnosing PHOA is particularly challenging in children, as they may report joint pain without showing the full range of symptoms, leading to potential misdiagnoses such as juvenile idiopathic arthritis (JIA).
  • A review of five pediatric patients revealed diagnostic dilemmas, with one case prompting a reevaluation of JIA and the cessation of ineffective treatments, emphasizing the need to consider PHOA in differential diagnoses of arthritis in children.

Article Abstract

Primary hypertrophic osteoarthropathy (PHOA) is a very rare disease. The typical triad of symptoms, i.e. digital clubbing, periosteal bone formation with bone and joint deformities and skin hypertrophy, may be accompanied by other specific conditions. In the majority of patients, the picture of the disease is incomplete. The dominant clinical symptom may be osteoarticular complaints. Moreover, the final confirmation of the diagnosis of the primary form of hypertrophic osteoarthropathy requires the analysis of much more frequent secondary causes of the disease. Diagnosing primary osteoarthropathy in children is particularly difficult. Some children report joint pain before the onset of the other symptoms of osteoarthropathy, while the physical and imaging examinations show features of arthritis. This can lead to misdiagnoses including the diagnosis of juvenile idiopathic arthritis (JIA) and the unnecessary use of immunosuppressive treatment. The present description of five patients from the Paediatric Rheumatology Department indicates diagnostic difficulties in children with PHOA. All of them were examined due to pain and features of arthritis. We observed an incomplete clinical picture of the disease. One patient required a revision of the previous diagnosis of JIA and discontinuation of ineffective treatment with disease-modifying antirheumatic drugs (DMARDs). PHOA should always be considered in the differential diagnosis of arthritis in children, due to the slow and often atypical development of symptoms, including the presence of pain and arthritis as the predominant symptom of the disease.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896987PMC
http://dx.doi.org/10.5114/ceji.2022.120171DOI Listing

Publication Analysis

Top Keywords

hypertrophic osteoarthropathy
12
primary hypertrophic
8
pain arthritis
8
arthritis children
8
picture disease
8
features arthritis
8
arthritis
6
osteoarthropathy
5
children
5
disease
5

Similar Publications

Hypertrophic osteoarthropathy (HOA: MIM 167100)) is classified into primary and secondary types. Primary HOA, also known as pachydermoperiostosis (PDP), is a rare genetic condition with distinct clinical features including digital clubbing, skin thickening, and periostosis. Secondary HOA often occurs as a paraneoplastic syndrome or is associated with systemic diseases.

View Article and Find Full Text PDF

Targeting Metabolomics in Primary Hypertrophic Osteoarthropathy: Uncovering Novel Insights into Disease Pathogenesis.

J Clin Endocrinol Metab

November 2024

Department of Endocrinology, Key Laboratory of Endocrinology, National Commission of Health, State Key Laboratory for Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing 100730, China.

Context: Primary hypertrophic osteoarthropathy (PHO) is a rare genetic disorder characterized by skeletal and skin abnormalities. Genetic defects in prostaglandin E2 (PGE2) metabolism are known to cause PHO. However, the global impact and clinical significance of eicosanoids and oxylipins beyond PGE2 remain to be elucidated.

View Article and Find Full Text PDF

An Unusual Case of Gastric Multiple Lesions With Skin and Joint Abnormalities.

Gastroenterology

November 2024

Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, China; Sichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China. Electronic address:

View Article and Find Full Text PDF
Article Synopsis
  • A 66-year-old male with recurrent stage IIIA non-small cell lung cancer (NSCLC) developed hypertrophic osteoarthropathy (HOA) before starting immunotherapy.
  • After receiving the immunotherapy drug durvalumab, the patient experienced significant relief from hand pain and complete resolution of his symptoms after five treatments.
  • This case is notable because it suggests durvalumab could help manage HOA in NSCLC patients, highlighting a need for additional research into how immune-checkpoint inhibitors interact with HOA and other related conditions.
View Article and Find Full Text PDF
Article Synopsis
  • * A patient with HOA secondary to lung adenocarcinoma presented with symptoms resembling rheumatoid arthritis, highlighting the need for careful diagnosis since antibodies typically associated with rheumatoid arthritis can be elevated in other conditions too.
  • * This case emphasizes the importance of considering HOA when diagnosing inflammatory arthritis in cancer patients, as proper identification and treatment of the underlying malignancy can significantly improve both rheumatologic and cancer-related outcomes.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!